Previous close | 40.62 |
Open | 33.60 |
Bid | 33.44 x 100 |
Ask | 42.48 x 200 |
Day's range | 33.16 - 35.20 |
52-week range | 21.38 - 48.81 |
Volume | |
Avg. volume | 1,297,758 |
Market cap | 3.623B |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.59 |
Earnings date | 31 Jul 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 49.33 |
Novavax stock surges after the vaccine maker signs a $1.2 billion licensing deal with France’s Sanofi, guidance from Akamai Technologies misses estimates, and Sweetgreen soars after the salad chain boosts its full-year revenue outlook.
The headline numbers for JFrog (FROG) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
JFrog (FROG) delivered earnings and revenue surprises of 14.29% and 1.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?